Edition:
United States

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,183.00DKK
10:59am EST
Change (% chg)

kr.-11.00 (-0.92%)
Prev Close
kr.1,194.00
Open
kr.1,210.00
Day's High
kr.1,210.00
Day's Low
kr.1,175.00
Volume
347,619
Avg. Vol
263,964
52-wk High
kr.1,489.00
52-wk Low
kr.1,096.00

Latest Key Developments (Source: Significant Developments)

Genmab Achieves $20 Million Milestone In Daratumumab Collaboration With Janssen
Wednesday, 29 Nov 2017 03:42pm EST 

Nov 29 (Reuters) - Genmab A/S ::GENMAB ACHIEVES USD 20 MILLION MILESTONE IN DARATUMUMAB COLLABORATION WITH JANSSEN AND UPDATES FINANCIAL GUIDANCE.GENMAB - EXPECT 2017 REVENUE TO BE IN RANGE OF DKK 2,240 - 2,440 MILLION.GENMAB - PAYMENT RELATES TO PHASE III ANDROMEDA STUDY OF DARATUMUMAB IN COMBINATION WITH CYCLOPHOSPHAMIDE, BORTEZOMIB & DEXAMETHASONE IN AMYLOIDOSIS.  Full Article

Genmab: $50 mln milestone payment in collaboration on Darzalex
Thursday, 16 Nov 2017 09:31pm EST 

Nov 17(Reuters) - GENMAB A/S : :SAID ON FRIDAY WILL RECEIVE MILESTONE PAYMENT OF USD 50 MILLION IN DARZALEX COLLABORATION WITH JANSSEN BIOTECH, INC..SAID MILESTONE TRIGGERED BY SALES OF DARZALEX REACHING USD 1 BILLION IN A CALENDAR YEAR.THE MILESTONE WAS INCLUDED IN GENMAB’S 2017 FINANCIAL GUIDANCE PUBLISHED ON NOVEMBER 14, 2017.  Full Article

‍Genmab says expect 2017 revenue to be in range of DKK 2,110 – 2,310 mln
Tuesday, 14 Nov 2017 02:50pm EST 

Nov 14 (Reuters) - Genmab ::‍GENMAB ACHIEVES USD 25 MILLION MILESTONE FOR FIRST COMMERCIAL SALE OF DARZALEX® (DARATUMUMAB) IN JAPAN AND UPDATES FINANCIAL GUIDANCE​.GENMAB SAYS ‍EXPECT 2017 REVENUE TO BE IN RANGE OF DKK 2.110 - 2.310 MILLION​.GENMAB-EXPECT DARZALEX ROYALTIES TO REMAIN IN RANGE OF DKK 930 - 1,100 MILLION WHICH ARE BASED ON ESTIMATED USD 1,100 - 1,300 MILLION OF DARZALEX SALES IN 2017​.‍NOW EXPECT OPERATING INCOME FOR 2017 TO BE APPROXIMATELY DKK 1,060 - 1,260 MILLION, COMPARED TO DKK 900 - 1,100 MILLION IN PREVIOUS GUIDANCE​.  Full Article

Genmab Q3 net loss DKK 5.7 mln, misses estimates
Wednesday, 8 Nov 2017 11:01am EST 

Nov 8 (Reuters) - GENMAB A/S ::GENMAB ANNOUNCES FINANCIAL RESULTS FOR THE FIRST NINE MONTHS OF 2017 <<>>.‍REVENUE WAS DKK 1,348 MILLION IN FIRST NINE MONTHS OF 2017 COMPARED TO DKK 889 MILLION IN FIRST NINE MONTHS OF 2016​.‍OPERATING INCOME WAS DKK 641 MILLION IN FIRST NINE MONTHS OF 2017 COMPARED TO DKK 345 MILLION IN FIRST NINE MONTHS OF 2016​.‍IS MAINTAINING ITS 2017 FINANCIAL GUIDANCE PUBLISHED ON FEBRUARY 22, 2017 AND REITERATED ON SEPTEMBER 27, 2017​.Q3 REVENUE DKK ‍​ 323.4 MILLION (REUTERS POLL DKK 333 MILLION).Q3 OPERATING RESULT DKK ‍​ 58.3 MILLION (REUTERS POLL DKK 59 MILLION).Q3 NET LOSS DKK ‍​5.7 MILLION (REUTERS POLL PROFIT DKK 67.3 MILLION).  Full Article

Genmab: ‍worldwide net sales of darzalex $317 mln in Q3
Tuesday, 17 Oct 2017 06:52am EDT 

Oct 17 (Reuters) - GENMAB A/S :GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR THIRD QUARTER OF 2017.‍WORLDWIDE NET SALES OF DARZALEX (DARATUMUMAB) AS REPORTED BY JOHNSON & JOHNSON WERE USD 317 MILLION IN Q3 OF 2017​.‍GENMAB WILL RECEIVE ROYALTIES ON WORLDWIDE NET SALES FROM JANSSEN BIOTECH, INC.​.  Full Article

Genmab and Seattle Genetics to start Phase II study of tisotumab vedotin
Tuesday, 10 Oct 2017 06:20am EDT 

Oct 10 (Reuters) - Genmab A/S :Genmab and Seattle Genetics to initiate new study of novel antibody-drug conjugate tisotumab vedotin in cervical cancer.Genmab - ‍companies plan to start enrolling patients by first half of 2018​.Genmab - ‍co, Seattle Genetics to start phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer​.  Full Article

Genmab: Darzalex approved for relapsed or refractory multiple myeloma in Japan
Wednesday, 27 Sep 2017 01:49am EDT 

Sept 27 (Reuters) - GENMAB A/S :ANNOUNCES APPROVAL OF DARZALEX® (DARATUMUMAB) FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN JAPAN .‍TO RECEIVE USD 25 MILLION IN MILESTONE PAYMENTS UPON FIRST COMMERCIAL SALE IN JAPAN​.‍IF FIRST COMMERCIAL SALE IS ACHIEVED PRIOR TO YEAR END, GENMAB EXPECTS TO UPDATE ITS FINANCIAL GUIDANCE AT THAT TIME​.FIRST COMMERCIAL SALE COULD TAKE PLACE IN EITHER LATE 2017 OR EARLY 2018, GENMAB IS NOT UPDATING ITS FINANCIAL GUIDANCE FOR 2017​.  Full Article

Genmab and Seattle Genetics to co-develop Tisotumab Vedotin for solid tumors
Tuesday, 29 Aug 2017 06:44am EDT 

Aug 29 (Reuters) - GENMAB A/S ::GENMAB AND SEATTLE GENETICS TO CO-DEVELOP TISOTUMAB VEDOTIN FOR SOLID TUMORS .COSTS AND PROFITS TO BE SHARED 50:50 GOING FORWARD.NEWS DOES NOT IMPACT 2017 FINANCIAL GUIDANCE.  Full Article

BRIEF-Genmab CEO confident to close some tech deals this year
Thursday, 10 Aug 2017 01:03am EDT 

Repeats Wednesday's story without changes to text:IS IN PROGRESSING TALKS WITH SEVERAL COMPANIES ON NEW TECHNOLOGY COLLABORATIONS, CONFIDENT TO CLOSE SOME DEALS IN 2017, AND SOME IN 2018.DEALS ARE MORE COMPLICATED TO MAKE NOW THAN EARLIER AS GENMAB WANTS CO-OWNERSHIP OR THE OPTION OF CO-OWNERSHIP AND THAT IS NOT WHAT THE LARGE BIOTECH AND PHARMA COMPANIES LIKE TO HEAR.NEW DEALS ARE GOING TO BE MORE FAVOURABLE TOWARDS GENMAB IN THE FUTURE AS ITS DRUGS ARE WORKING WELL AND POTENTIAL PARTNERS ARE VERY EAGER TO GET ACCESS TO ITS TECHNOLOGIES.IS MOVING AGGRESSIVELY FORWARD TOGETHER WITH JANSSEN ON SUBCUTANEOUS FORMULATION OF DARATUMUMAB.IT IS INCREDIBLY IMPORTANT THAT GENMAB HAS REACHED AGREEMENT WITH REGULATORS ON HOW TO GET SUBCUTANEOUS FORMULATION OF DARATUMUMAB TO MARKET.STILL SEE LOT OF UNCERTAINTIES IN 2017, STILL NEED TO SEE PICK-UP IN DARZALEX SALES IN H2.  Full Article

Genmab Q2 net profit at DKK 307.3 million
Wednesday, 9 Aug 2017 11:03am EDT 

Aug 9 (Reuters) - GENMAB ::SAYS ‍REVENUE WAS DKK 1,024 MILLION IN FIRST HALF OF 2017 COMPARED TO DKK 524 MILLION IN FIRST HALF OF 2016​.‍MAINTAINS 2017 FINANCIAL GUIDANCE​.MAINTAINING ITS 2017 FINANCIAL GUIDANCE PUBLISHED ON FEBRUARY 22, 2017 AND REITERATED ON MAY 10, 2017.Q2 REVENUE DKK ‍773.3​ MILLION (REUTERS POLL DKK 716 MILLION).Q2 NET PROFIT DKK 307.3 MILLION (REUTERS POLL DKK 400 MILLION).Q2 ADJUSTED OPERATING PROFIT DKK 536.4‍​ MILLION (REUTERS POLL DKK 469 MILLION).  Full Article

Photo

Genmab and Johnson & Johnson 'love' partnership as some ponder takeover

LONDON Genmab was Europe's second biggest biotech company, until its partner Johnson & Johnson bought Switzerland's Actelion for $30 billion this year and propelled the Danish antibody specialist to the top spot.